Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

ABSTRACT:

Importance

Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available.

Objective

To compare on-treatment weight loss and rates of gastrointestinal adverse events (AEs) among adults with overweight or obesity receiving tirzepatide or semaglutide labeled for type 2 diabetes (T2D) in a clinical setting.

Design, setting, and participants

In this cohort study, adults with overweight or obesity receiving semaglutide or tirzepatide between May 2022 and September 2023 were identified using electronic health record (EHR) data linked to dispensing information from a collective of US health care systems. On-treatment weight outcomes through Nove

SUBMITTER: Rodriguez PJ 

PROVIDER: S-EPMC11231910 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature